Compare MHO & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHO | ARQT |
|---|---|---|
| Founded | 1976 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 1995 | 2020 |
| Metric | MHO | ARQT |
|---|---|---|
| Price | $141.17 | $23.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $160.00 | $34.00 |
| AVG Volume (30 Days) | 152.4K | ★ 1.6M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 5.57 | 0.03 |
| Revenue | ★ $4,417,781,000.00 | $376,072,000.00 |
| Revenue This Year | $0.66 | $34.85 |
| Revenue Next Year | $6.97 | $29.39 |
| P/E Ratio | ★ $25.73 | $813.00 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $116.78 | $16.62 |
| 52 Week High | $163.66 | $31.77 |
| Indicator | MHO | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 37.51 | 39.92 |
| Support Level | $125.88 | $22.73 |
| Resistance Level | $155.74 | $25.25 |
| Average True Range (ATR) | 3.33 | 0.89 |
| MACD | -1.07 | -0.05 |
| Stochastic Oscillator | 9.11 | 20.00 |
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.